Utilizing genomics to identify novel immunotherapeutic targets in multiple myeloma high-risk subgroups
Sign Up to like & getrecommendations! Published in 2025 at "Genome Medicine"
DOI: 10.1186/s13073-025-01503-y
Abstract: Immunotherapy is now standard of care for multiple myeloma, where the most common targets are B cell maturation antigen, CD38, and G protein-coupled receptor class C group 5 member D but strategies to identify additional… read more here.
Keywords: multiple myeloma; utilizing genomics; risk subgroups; high risk ... See more keywords